APA (7th ed.) Citation

Lin, M., Ye, R., Jhou, H., Chen, H., Kao, L., Hsieh, T. Y., . . . Lee, C. (2025). Immune checkpoint inhibitor therapy and risk of type 1 diabetes mellitus in metastatic cancer patients. Diabetology & Metabolic Syndrome, 17(1), 1. https://doi.org/10.1186/s13098-025-01940-0

Chicago Style (17th ed.) Citation

Lin, Ming-Hsun, et al. "Immune Checkpoint Inhibitor Therapy and Risk of Type 1 Diabetes Mellitus in Metastatic Cancer Patients." Diabetology & Metabolic Syndrome 17, no. 1 (2025): 1. https://doi.org/10.1186/s13098-025-01940-0.

MLA (9th ed.) Citation

Lin, Ming-Hsun, et al. "Immune Checkpoint Inhibitor Therapy and Risk of Type 1 Diabetes Mellitus in Metastatic Cancer Patients." Diabetology & Metabolic Syndrome, vol. 17, no. 1, 2025, p. 1, https://doi.org/10.1186/s13098-025-01940-0.